Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
SC TC EN
SC TC EN
Science and Medicine
Technology Platforms Products Center
About Us
Full Value Chain
News
Investor Relations
Announcements and Circulars Corporate Governance Investor Inquiry
Contact Us
Vascepa®

Product List
Product Overview
Guideline Recommendations
Academic Publications
Vascepa®

Icosapent Ethyl Soft Capsules

The first TG-lowering drug indicated for cardiovascular risk reduction in China
The first TG-lowering drug indicated for cardiovascular risk reduction in China
With pleiotropic effects of anti-inflammation, anti-thrombosis, anti-oxidant and plaque reversal for CV benefits
With pleiotropic effects of anti-inflammation, anti-thrombosis, anti-oxidant and plaque reversal for CV benefits
Has patented production technology of high purity EPA products with EPA≥96%, without DHA
Has patented production technology of high purity EPA products with EPA≥96%, without DHA
The following product information is intended for use by healthcare professionals only.
The following product may not have been approved and/or licensed for marketing in all countries where this website is accessible.
Vascepa®
Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Product information stated by NMPA in Approved Drug Catalog of China.
【Name】

Generic Name：Icosapent Ethyl Soft Capsules

Brand Name：VASCEPA®（唯思沛®） 

Chinese Pinyin：Ershitanwuxisuanyizhi Ruanjiaonang
【Ingredients】

Active Ingredient: icosapent ethyl

Excipients：gelatin, glycerin, maltitol, sorbitol,purified water and medicinalInk.

【Appearance】

VASCEPA, a lipid-regulating agent, is supplied as either a 0.5 gram or a 1 gram amber-colored, liquid-filled soft gelatin capsule for oral use.

【 Indications】

As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

As an adjunct to statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable  angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease.

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been  determined.

【Specification】
1.0g
For detailed product information, please download the full package insert (PDF).
Directions for Use Download
(for medical professionals only)
Adverse Event Reporting

Email: pv@eddingpharm.com

Hotline: 0512-67611023

Guideline Recommendations
Abroad

2024（CKM）DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

2025 American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias， ESC Clinical Practice Guidelines

Domestic

2023 China Guidelines for the Management of Blood Lipids

2022 Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts’ Committee Of National Society Of Cardiometabolic Medicine

2023 Multidisciplinary Expert Consensus on the Clinical Management of Hypertriglyceridemia

Academic Publications
Bhatt D, Steg G, Brinton E, Jacobson T, Miller M, Tardif JC, Ketchum S, Doyle Jr R, Murphy S, Soni P, Braeckman R, Juliano R, Ballantyne C. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial [abstract 127]. Clin Cardiol. 2017;40(suppl 1):14-15.
Journal Name: Clin Cardiol.
Year: 2017
Read More
Miller M, Bhatt D, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum S, Doyle R, Tardif J-C, Ballantyne CM. Effectiveness of icosapent ethyl on first and total cardiovascular events in the metabolic syndrome: REDUCE-IT MetSyn. Circulation. 2023;148:12542.
Journal Name: Circulation.
Year: 2023
Read More
Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22.
Journal name: N Engl J Med.
Year: 2019
Read More
Technology Platforms
Product Center
About Us
Full Value Chain
News
Investor Relations
Contact Us

沪ICP备2021007464号

Copyright © 2025 design by EDDING

药监局备案号: (沪) -非经营性-2021-0038